Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,741 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Discovery and clinical introduction of first-in-class imipridone ONC201.
Allen JE, Kline CL, Prabhu VV, Wagner J, Ishizawa J, Madhukar N, Lev A, Baumeister M, Zhou L, Lulla A, Stogniew M, Schalop L, Benes C, Kaufman HL, Pottorf RS, Nallaganchu BR, Olson GL, Al-Mulla F, Duvic M, Wu GS, Dicker DT, Talekar MK, Lim B, Elemento O, Oster W, Bertino J, Flaherty K, Wang ML, Borthakur G, Andreeff M, Stein M, El-Deiry WS. Allen JE, et al. Among authors: lim b. Oncotarget. 2016 Nov 8;7(45):74380-74392. doi: 10.18632/oncotarget.11814. Oncotarget. 2016. PMID: 27602582 Free PMC article. Review.
Genetic and Pharmacological Screens Converge in Identifying FLIP, BCL2, and IAP Proteins as Key Regulators of Sensitivity to the TRAIL-Inducing Anticancer Agent ONC201/TIC10.
Allen JE, Prabhu VV, Talekar M, van den Heuvel AP, Lim B, Dicker DT, Fritz JL, Beck A, El-Deiry WS. Allen JE, et al. Among authors: lim b. Cancer Res. 2015 Apr 15;75(8):1668-74. doi: 10.1158/0008-5472.CAN-14-2356. Epub 2015 Feb 13. Cancer Res. 2015. PMID: 25681273 Free PMC article.
Targeting TRAIL in the treatment of cancer: new developments.
Lim B, Allen JE, Prabhu VV, Talekar MK, Finnberg NK, El-Deiry WS. Lim B, et al. Expert Opin Ther Targets. 2015;19(9):1171-85. doi: 10.1517/14728222.2015.1049838. Epub 2015 May 25. Expert Opin Ther Targets. 2015. PMID: 26004811 Review.
Dynamic changes in CD44v-positive cells after preoperative anti-HER2 therapy and its correlation with pathologic complete response in HER2-positive breast cancer.
Yamauchi T, Espinosa Fernandez JR, Imamura CK, Yamauchi H, Jinno H, Takahashi M, Kitagawa Y, Nakamura S, Lim B, Krishnamurthy S, Reuben JM, Liu D, Tripathy D, Chen H, Takebe N, Saya H, Ueno NT. Yamauchi T, et al. Among authors: lim b. Oncotarget. 2018 Jan 4;9(6):6872-6882. doi: 10.18632/oncotarget.23914. eCollection 2018 Jan 23. Oncotarget. 2018. PMID: 29467936 Free PMC article.
First-in-Human Phase 1b Trial of Quinacrine Plus Capecitabine in Patients With Refractory Metastatic Colorectal Cancer.
Winer A, Denlinger CS, Vijayvergia N, Cohen SJ, Astaturov I, Dotan E, Gallant JN, Wang EW, Kunkel M, Lim B, Harvey HA, Sivik J, Korzekwa K, Ruth K, White K, Cooper HS, Ross EA, Zhou L, El-Deiry WS. Winer A, et al. Among authors: lim b. Clin Colorectal Cancer. 2021 Mar;20(1):e43-e52. doi: 10.1016/j.clcc.2020.08.003. Epub 2020 Aug 19. Clin Colorectal Cancer. 2021. PMID: 32972830 Free article. Clinical Trial.
Correction: Discovery and clinical introduction of first-in-class imipridone ONC201.
Allen JE, Kline CLB, Prabhu VV, Wagner J, Ishizawa J, Madhukar N, Lev A, Baumeister M, Zhou L, Lulla A, Stogniew M, Schalop L, Benes C, Kaufman HL, Pottorf RS, Nallaganchu BR, Olson GL, Al-Mulla F, Duvic M, Wu GS, Dicker DT, Talekar MK, Lim B, Elemento O, Oster W, Bertino J, Flaherty K, Wang ML, Borthakur G, Andreeff M, Stein M, El-Deiry WS. Allen JE, et al. Among authors: lim b. Oncotarget. 2021 Oct 12;12(21):2231. doi: 10.18632/oncotarget.28012. eCollection 2021 Oct 12. Oncotarget. 2021. PMID: 34676056 Free PMC article.
2,741 results